Olodaterol

Inhalation/Respiratory
Maintenance therapy in chronic obstructive pulmonary disease

Monotherapy in the treatment of asthma. As primary treatment of asthma, acute episodes of bronchospasm, and acutely deteriorating COPD.

Patient with CV disease (e.g. arrhythmia, coronary insufficiency, hypertension, heart failure), diabetes mellitus, hyperthyroidism, hypokalaemia, seizure disorder, aneurysm. Pregnancy and lactation.

Significant: Hypersensitivity (e.g. angioedema), increased serum glucose, decreased serum K, CNS stimulation/excitation, thyroid activity stimulation; CV effects (e.g. increased pulse rate, and blood pressure, ECG changes), hypokalaemia, hyperglycaemia.
Infections and infestations: UTI.
Musculoskeletal and connective tissue disorders: Arthralgia, back pain.
Nervous system disorders: Dizziness.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, bronchitis.
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Paradoxical bronchospasm.

Inhalation/Respiratory: C

This drug may cause dizziness, if affected, do not drive or operate machinery.

Monitor pulmonary function including FEV₁ and FVC, blood pressure, heart rate, serum glucose and K levels; CNS stimulation.

Symptoms: Myocardial ischaemia, angina pectoris, hypertension or hypotension, tachycardia, arrhythmia, palpitation, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasm, nausea, fatigue, malaise, hypokalaemia, hyperglycaemia, metabolic acidosis. Management: Symptomatic and supportive treatment. May consider use of cardioselective β-blockers with extreme caution. Cardiac monitoring.

Increased risk of adverse CV effect with halogenated hydrocarbon anaesthetics. Increased risk of ventricular arrhythmia with drugs that prolong QT-interval (e.g. MAOIs, TCAs). Antagonistic effect with β-blockers. Increased risk of hypokalaemia with xanthine derivatives, corticosteroids, or non-K sparing diuretics. Increased plasma concentration with CYP enzyme inhibitor (e.g. ketoconazole).
Potentially Fatal: Additive sympathomimetic effect with other long-acting beta₂-adrenergic agents.

Description:
Mechanism of Action: Olodaterol is a long acting beta₂-receptor agonist. It stimulates intracellular adenyl cyclase, thereby increasing cyclic-3′, 5′-adenosine monophosphate (cAMP) levels, resulting in bronchodilation by relaxation of airway smooth muscle.
Onset: 5 minutes.
Duration: Approx 24 hours.
Pharmacokinetics:
Absorption: Rapidly absorbed systemically via lungs. Time to peak plasma concentration: 10-20 minutes. Absolute bioavailability: Approx 30%.
Distribution: Volume of distribution: 1,110 L. Plasma protein binding: Approx 60%.
Metabolism: Metabolised via direct glucuronidation by UGT2B7, UGT1A1, UGT1A7, and UGT1A9 and via O-demethylation primarily by CYP2C9 and CYP2C8; further metabolised via conjugation.
Excretion: Via urine (5-7%, as unchanged drug). Elimination half-life: 7.5 hours.

Source: National Center for Biotechnology Information. PubChem Database. Olodaterol, CID=11504295, https://pubchem.ncbi.nlm.nih.gov/compound/Olodaterol (accessed on Jan. 22, 2020)

Store at 25°C. Do not freeze.

Antiasthmatic & COPD Preparations

R03AC19 - olodaterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.

Anon. Olodaterol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/02/2018.

Buckingham R (ed). Olodaterol Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/02/2018.

Joint Formulary Committee. Olodaterol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/02/2018.

McEvoy GK, Snow EK, Miller J et al (eds). Olodaterol Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 07/02/2018.

Olodaterol. Drugs and Lactation Database (LactMed) [Internet]. Bethesda, MD. U.S. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501922/. Accessed 09/02/2018.

Striverdi Respimat Inhalation Spray, Metered (Boehringer Ingelheim Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/02/2018.